ログイン

CLINICAL CHEMISTRY HARR

CLINICAL CHEMISTRY HARR
69問 • 1年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    Which of the following conditions will increase total T4 by increasing TBG? A. Acute illness B. Anabolic steroid use C. Nephrotic syndrome D. Pregnancy or estrogens

    D. Pregnancy or estrogens

  • 2

    Select the most appropriate single screening test for thyroid disease. A. Free thyroxine index B. Total T3 assay C. Total T4 D. TSH assay

    D. TSH assay

  • 3

    The serum TSH level is almost absent in: A. Primary hyperthyroidism B. Primary hypothyroidism C. Secondary hyperthyroidism D. Euthyroid sick syndrome

    A. Primary hyperthyroidism

  • 4

    Which assay is used to confirm difficult cases of hypothyroidism? A. Free T3 assay B. Free thyroxine index C. Thyrotropin-releasing hormone (TRH) stimulation test D. TBG assay

    C. Thyrotropin-releasing hormone (TRH) stimulation test

  • 5

    Which of the following statements is true regarding reverse T3 (rT3)? A. Formed in the blood by degradation of T4 B. Physiologically active, but less than T3 C. Decreased in euthyroid sick syndrome D. Interferes with the measurement of serum T3

    A. Formed in the blood by degradation of T4

  • 6

    A patient has an elevated serum T3 and free T4 and undetectable TSH. What is the most likely cause of these results? A. Primary hyperthyroidism B. Secondary hyperthyroidism C. Euthyroid with increased thyroxine-binding proteins D. Euthyroid sick syndrome

    A. Primary hyperthyroidism

  • 7

    A serum thyroid panel reveals an increase in total T4, normal TSH, and normal free T4. What is the most likely cause of these results? A. Primary hyperthyroidism B. Secondary hyperthyroidism C. Euthyroid with increased thyroxine-binding protein D. Subclinical hypothyroidism

    C. Euthyroid with increased thyroxine-binding protein

  • 8

    Which statement about TSH and T4 in early pregnancy is correct? A. TSH and thyroid hormones fall B. TSH falls and thyroid hormones rise C. TSH and thyroid hormones both rise D. TSH rises and thyroid hormones fall

    B. TSH falls and thyroid hormones rise

  • 9

    In which case might a very low plasma TSH result not correlate with thyroid status? A. Euthyroid sick syndrome B. Congenital hypothyroidism C. When TBG is elevated D. After high-dose corticosteroid treatment

    D. After high-dose corticosteroid treatment

  • 10

    In which of the following cases is qualitative analysis of the drug usually adequate? A. To determine whether the dose of a drug with a low therapeutic index is likely to be toxic B. To determine whether a patient is complying with the physician’s instructions C. To adjust dose if individual differences or disease alter expected response D. To determine whether the patient has been taking amphetamines

    D. To determine whether the patient has been taking amphetamines

  • 11

    The term pharmacokinetics refers to the: A. Relationship between drug dose and the drug blood level B. Concentration of drug at its sites of action C. Relationship between blood concentration and therapeutic response D. The relationship between blood and tissue drug levels

    A. Relationship between drug dose and the drug blood level

  • 12

    The term pharmacodynamics is an expression of the relationship between: A. Dose and physiological effect B. Drug concentration at target sites and physiological effect C. Time and serum drug concentration D. Blood and tissue drug levels

    B. Drug concentration at target sites and physiological effect

  • 13

    The study of pharmacogenomics involves which type of testing? A. Family studies to determine the inheritance of drug resistance B. Testing drugs with cell cultures to determine the minimum toxic dosage C. Testing for single nucleotide polymorphisms known to affect drug metabolism D. Comparison of dose-response curves between family members

    C. Testing for single nucleotide polymorphisms known to affect drug metabolism

  • 14

    Select the five pharmacological parameters that determine serum drug concentration. A. Absorption, anabolism, perfusion, bioactivation, excretion B. Liberation, equilibration, biotransformation, reabsorption, elimination C. Liberation, absorption, distribution, metabolism, excretion D. Ingestion, conjugation, integration, metabolism, elimination

    C. Liberation, absorption, distribution, metabolism, excretion

  • 15

    Which route of administration is associated with 100% bioavailability? A. Sublingual B. Intramuscular C. Oral D. Intravenous

    D. Intravenous

  • 16

    The phrase “first-pass hepatic metabolism” means that: A. One hundred percent of a drug is excreted by the liver B. All drug is inactivated by hepatic enzymes after one pass through the liver C. Some drug is metabolized from the portal circulation, reducing bioavailability D. The drug must be metabolized in the liver to an active form

    C. Some drug is metabolized from the portal circulation, reducing bioavailability

  • 17

    Which formula can be used to estimate dosage needed to give a desired steady-state blood level? A. Dose per hour = clearance (milligrams per hour) × average concentration at steady state ÷ f B. Dose per day = fraction absorbed – fraction excreted C. Dose = fraction absorbed × (1/protein-bound fraction) D. Dose per day = half-life × log Vd (volume distribution)

    A. Dose per hour = clearance (milligrams per hour) × average concentration at steady state ÷ f

  • 18

    Which statement is true regarding the volume distribution (Vd) of a drug? A. Vd is equal to the peak blood concentration divided by the dose given B. Vd is the theoretical volume in liters into which the drug distributes C. The higher the Vd, the lower the dose needed to reach the desired blood level of drug D. The Vd is the principal determinant of the dosing interval

    B. Vd is the theoretical volume in liters into which the drug distributes

  • 19

    For drugs with first-order elimination, which statement about drug clearance is true? A. Clearance = elimination rate ÷ serum level B. It is most often performed by the liver C. It is directly related to half-life D. Clearance rate is independent of dose

    A. Clearance = elimination rate ÷ serum level

  • 20

    Which statement about steady-state drug levels is true? A. The absorbed drug must be greater than the amount excreted B. Steady state can be measured after two elimination half-lives C. Constant intravenous infusion will give the same minima and maxima as an oral dose D. Oral dosing intervals give peaks and troughs in the dose-response curve

    D. Oral dosing intervals give peaks and troughs in the dose-response curve

  • 21

    If too small a peak–trough difference is seen for a drug given orally, then: A. The dose should be decreased B. Time between doses should be decreased C. Dose interval should be increased D. Dose per day and time between doses should be decreased

    C. Dose interval should be increased

  • 22

    If the peak level is appropriate but the trough level too low at steady state, then the dose interval should: A. Be lengthened without changing the dose per day B. Be lengthened and dose rate decreased C. Not be changed, but dose per day increased D. Be shortened, but dose per day not changed

    D. Be shortened, but dose per day not changed

  • 23

    If the steady-state drug level is too high, the best course of action is to: A. Decrease the dose B. Decrease the dose interval C. Decrease the dose and decrease the dose interval D. Change the route of administration

    A. Decrease the dose

  • 24

    When should blood samples for trough drug levels be collected? A. 30 minutes after peak levels B. 45 minutes before the next dose C. 1–2 hours after the last dose D. Immediately before the next dose is given

    D. Immediately before the next dose is given

  • 25

    Blood sample collection time for peak drug levels: A. Varies with the drug, depending on its rate of absorption B. Is independent of drug formulation C. Is independent of the route of administration D. Is 30 minutes after a bolus intravenous injection is completed

    A. Varies with the drug, depending on its rate of absorption

  • 26

    Which could account for drug toxicity following a normally prescribed dose? A. Decreased renal clearance caused by kidney disease B. Discontinuance or administration of another drug C. Altered serum protein binding caused by disease D. All of these options

    D. All of these options

  • 27

    Select the elimination model that best describes most oral drugs. A. One compartment, linear first-order elimination B. Michaelis–Menton or concentration-dependent elimination C. Two compartment with a biphasic elimination curve D. Logarithmic elimination

    A. One compartment, linear first-order elimination

  • 28

    Drugs rapidly infused intravenously usually follow which elimination model? A. One compartment, first order B. One compartment, logarithmic C. Biphasic or two compartment with serum level rapidly falling in the first phase D. Michaelis–Menton or concentration-dependent elimination

    C. Biphasic or two compartment with serum level rapidly falling in the first phase

  • 29

    Which fact must be considered when evaluating a patient who displays signs of drug toxicity? A. Drug metabolites (e.g., N-acetylprocainamide) may need to be measured as well as parent drug B. If the concentration of total drug is within therapeutic limits, the concentration of free drug cannot be toxic C. If the drug has a wide therapeutic index, then it will not be toxic D. A drug level cannot be toxic if the trough is within the published therapeutic range

    A. Drug metabolites (e.g., N-acetylprocainamide) may need to be measured as well as parent drug

  • 30

    When a therapeutic drug is suspected of causing toxicity, which specimen is the most appropriate for an initial investigation? A. Trough blood sample B. Peak blood sample C. Urine at the time of symptoms D. Gastric fluid at the time of symptoms

    B. Peak blood sample

  • 31

    For a drug that follows first-order pharmacokinetics, adjustment of dosage to achieve the desired blood level can be made using which formula?

    A

  • 32

    For which drug group are both peak and trough measurements usually required? A. Antiarrhythmics B. Analgesics C. Tricyclic antidepressants D. Aminoglycoside antibiotics

    D. Aminoglycoside antibiotics

  • 33

    Which of the following statements about TLC for drug screening is true? A. Acidic drugs are extracted in an alkaline nonpolar solvent B. A drug is identified by comparing its Rf value and staining to standards C. Testing must be performed using a urine sample D. Opiates and other alkaloids are extracted at an acid pH

    B. A drug is identified by comparing its Rf value and staining to standards

  • 34

    The EMIT for drugs of abuse uses an: A. Antibody conjugated to a drug B. Enzyme conjugated to an antibody C. Enzyme conjugated to a drug D. Antibody bound to a solid phase

    C. Enzyme conjugated to a drug

  • 35

    Which statement about EMIT is true? A. Enzyme activity is inversely proportional to drug level B. Formation of NADH is monitored at 340 nm C. ALP is the commonly used conjugate D. Assay use is restricted to serum

    B. Formation of NADH is monitored at 340 nm

  • 36

    Which statement regarding cloned enzyme donor immunoassay (CEDIA) is true? A. The enzyme used is glucose-6-phosphate dehydrogenase B. The enzyme donor and acceptor molecules are fragments of β-galactosidase C. Drug concentration is inversely related to fluorescence D. The antibody is covalently linked to the enzyme donor

    B. The enzyme donor and acceptor molecules are fragments of ß-galactosidase

  • 37

    Which statement is true regarding particle-enhanced turbidimetric inhibition immunoassay methods for therapeutic drugs? A. Drug concentration is proportional to light scatter B. Magnetic separation is needed to remove unbound conjugate C. When particle-bound drug binds to antibody, light scattering is increased D. Two antibodies to the drug are needed

    C. When particle-bound drug binds to antibody, light scattering is increased

  • 38

    Quantitation of a drug by gas chromatography–mass spectroscopy (GC-MS) is usually performed in which mode? A. Total ion chromatography B. Selective ion monitoring C. Ion subtraction D. Selective reaction monitoring

    B. Selective ion monitoring

  • 39

    SITUATION: A urine sample is received in the laboratory with the appropriate custody control form, and a request for drug of abuse screening. Which test result would be cause for rejecting the sample? A. Temperature after collection 95°F B. pH 5.0 C. Specific gravity 1.005 D. Creatinine 5 mg/dL

    D. Creatinine 5 mg/dL

  • 40

    Which substance has the longest detection time? A. Amphetamines B. Cocaine C. Benzodiazepines D. Marijuana

    D. Marijuana

  • 41

    Which statement about the measurement of carboxyhemoglobin is true? A. Treatment with alkaline dithionite is used to convert carboxyhemoglobin to oxyhemoglobin B. Oxyhemoglobin has no absorbance at 540 nm, but carboxyhemoglobin does C. Bichromatic analysis is required in order to eliminate interference by oxyhemoglobin D. Carboxyhemoglobin can be measured by potentiometry

    C. Bichromatic analysis is required in order to eliminate interference by oxyhemoglobin

  • 42

    Which of the following statements about blood alcohol measurement is correct? A. Symptoms of intoxication usually begin when the level exceeds 0.05% w/v B. The skin puncture site should be disinfected with isopropanol C. The reference method is based upon enzymatic oxidation of ethanol by alcohol dehydrogenase D. Gas chromatography methods require extraction of ethanol from serum

    A. Symptoms of intoxication usually begin when the level exceeds 0.05% w/v

  • 43

    Which specimen is the sample of choice for lead screening? A. Whole blood B. Hair C. Serum D. Urine

    A. Whole blood

  • 44

    Which of the following enzymes can be used to measure plasma or serum salicylate? A. Peroxidase B. Salicylate esterase C. Salicylate hydroxylase D. p-Aminosalicylate oxidase

    C. Salicylate hydroxylase

  • 45

    Which of the following tests is least essential to the operation of an emergency department at a general hospital? A. Carboxyhemoglobin B. Osmolality C. Salicylate D. Lead

    D. Lead

  • 46

    Which of the following trace elements is considered an essential micronutrient? A. Thallium B. Aluminum C. Mercury D. Selenium

    D. Selenium

  • 47

    When measuring trace metals in blood other than lead, what type of tube should be used? A. Navy blue top B. Green top C. Purple top D. Red top

    A. Navy blue top

  • 48

    Which whole-blood level is suggestive of excessive exposure to lead in children but not adults? A. 4 μg/dL B. 14 μg/dL C. 28 μg/dL D. 32 μg/dL

    B. 14 μg/dL

  • 49

    What are the likely laboratory findings in a person suspected of having Wilson’s disease? A. Blood copper and ceruloplasmin low, urinary copper excretion high B. Blood and urine copper concentration high, ceruloplasmin low C. Blood and urine copper concentration high, ceruloplasmin high D. Blood and urine copper concentration low, ceruloplasmin low

    A. Blood copper and ceruloplasmin low, urinary copper excretion high

  • 50

    Which of the following tumor markers is classified as a tumor suppressor gene? A. BRCA-1 B. Carcinoembryonic antigen (CEA) C. Human chorionic gonadotropin (hCG) D. Nuclear matrix protein

    A. BRCA-1

  • 51

    In general, in which of the following situations is the analysis of a tumor marker most useful? A. Testing for recurrence B. Prognosis C. Screening D. Diagnosis

    A. Testing for recurrence

  • 52

    Which of the following enzymes is increased in persons with prostate and small-cell lung cancer? A. Creatine kinase-1 (CK-1) B. Gamma glutamyl transferase (GGT) C. Amylase D. Lactate dehydrogenase

    A. Creatine kinase-1 (CK-1)

  • 53

    Which of the following is the best analyte to monitor for recurrence of ovarian cancer? A. CA-15-3 B. CA-19-9 C. CA-125 D. CEA

    C. CA-125

  • 54

    Which tumor marker is associated with cancer of the urinary bladder? A. CA-19-9 B. CA-72-4 C. Nuclear matrix protein D. Cathepsin-D

    C. Nuclear matrix protein

  • 55

    A person presents with a cushingoid appearance and an elevated 24-hour urinary cortisol level. The plasma adrenocotropic hormone (ACTH) is very elevated, and the physician suspects the cause is ectopic ACTH production. Which test would be most useful in substantiating this diagnosis? A. Plasma cortisol B. CA-50 C. Alkaline phosphatase isoenzymes D. AFP

    C. Alkaline phosphatase isoenzymes

  • 56

    Which of the following tumor markers is used to monitor persons with breast cancer for recurrence of disease? A. Cathepsin-D B. CA-15-3 C. Retinoblastoma gene D. Estrogen receptor (ER)

    B. CA-15-3

  • 57

    Which of the following statements regarding the Philadelphia chromosome is true? A. It is seen exclusively in chronic myelogenous leukemia B. It results from a translocation C. It appears as a short-arm deletion of chromosome 21 D. It is associated with a poor prognosis

    B. It results from a translocation

  • 58

    What is the primary clinical utility of measuring CEA? A. Diagnosis of liver cancer B. Diagnosis of colorectal cancer C. Screening for cancers of endodermal origin D. Monitoring for recurrence of cancer

    D. Monitoring for recurrence of cancer

  • 59

    Which tumor marker is used to determine the usefulness of trastuzumab (Herceptin) therapy for breast cancer? A. PR B. CEA C. HER-2/neu D. Myc

    C. HER-2/ne

  • 60

    A person is suspected of having testicular cancer. Which type of hCG test would be most useful? A. Plasma immunoassay for intact hCG only B. Plasma immunoassay for intact hCG and the β-hCG subunit C. Plasma immunoassay for the free alpha and β-hCG subunits D. Urine assay for hCG β core

    B. Plasma immunoassay for intact hCG and the β-hCG subunit

  • 61

    A patient treated for a germ cell tumor has a total and free β-hCG assay performed prior to surgery. The result is 40,000 mIU/mL. One week following surgery, the hCG is 5,000 mIU/mL. Chemotherapy is started, and the hCG is measured 1 week later and found to be 10,000 mIU/mL. What does this indicate? A. Recurrence of the tumor B. Falsely increased hCG owing to drug interference with the assay C. Analytical error with the test reported as 5,000 mIU/mL D. Transient hCG increase caused by chemotherapy

    D. Transient hCG increase caused by chemotherapy

  • 62

    Which set of results for ER and PR is associated with the highest likelihood of a favorable response to treatment with estrogen-suppression therapy (tamoxifen)? A. ER positive, PR positive B. ER positive, PR negative C. ER negative, PR positive D. ER negative, PR negative

    A. ER positive, PR positive

  • 63

    Which type of cancer is associated with the highest level of AFP? A. Hepatoma B. Ovarian cancer C. Testicular cancer D. Breast cancer

    A. Hepatoma

  • 64

    Which of the following assays is recommended as a screening test for colorectal cancer in persons over 50 years old? A. CEA B. AFP C. Occult blood D. Fecal trypsin

    C. Occult blood

  • 65

    Which of the following assays is used to determine the risk of developing cancer? A. Epidermal growth factor receptor (EGF-R) B. Squamous cell carcinoma antigen (SCC) C. c-erb B-2 gene expression D. p53 gene mutation

    D. p53 gene mutation

  • 66

    A person has an elevated 24-hour urinary homovanillic acid (HVA) and vanillymandelic acid (VMA). Urinary metanephrines, chromogranin A, and neuron-specific enolase are also elevated but 5-hydroxyindoleacetic acid is within the reference range. What is the most likely diagnosis? A. Carcinoid tumors of the intestine B. Pheochromocytoma C. Neuroblastoma D. Pancreatic cancer

    C. Neuroblastoma

  • 67

    In which of the following conditions is PSA least likely to be increased? A. Precancerous lesions of the prostate B. Postprostate biopsy C. Benign prostatic hypertrophy D. Post–digital rectal examination

    D. Post–digital rectal examination

  • 68

    Which of the following statements regarding PSA is true? A. Complexed PSA in plasma is normally less than free PSA B. Free PSA below 25% is associated with malignant disease C. A total PSA below 4 ng/mL rules out malignant disease D. A total PSA above 10 ng/mL is diagnostic of malignant disease

    B. Free PSA below 25% is associated with malignant disease

  • 69

    A 55-year-old male with early stage prostate cancer diagnosed by biopsy had his prostate gland removed (simple prostatectomy). His PSA prior to surgery was 10.0 ng/mL. If the surgery was successful in completely removing the tumor cells, what would the PSA result be 1 month after surgery? A. Undetectable B. 1–3 ng/mL C. Less than 4 ng/mL D. Less than 10 ng/mL

    A. Undetectable

  • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    Which of the following conditions will increase total T4 by increasing TBG? A. Acute illness B. Anabolic steroid use C. Nephrotic syndrome D. Pregnancy or estrogens

    D. Pregnancy or estrogens

  • 2

    Select the most appropriate single screening test for thyroid disease. A. Free thyroxine index B. Total T3 assay C. Total T4 D. TSH assay

    D. TSH assay

  • 3

    The serum TSH level is almost absent in: A. Primary hyperthyroidism B. Primary hypothyroidism C. Secondary hyperthyroidism D. Euthyroid sick syndrome

    A. Primary hyperthyroidism

  • 4

    Which assay is used to confirm difficult cases of hypothyroidism? A. Free T3 assay B. Free thyroxine index C. Thyrotropin-releasing hormone (TRH) stimulation test D. TBG assay

    C. Thyrotropin-releasing hormone (TRH) stimulation test

  • 5

    Which of the following statements is true regarding reverse T3 (rT3)? A. Formed in the blood by degradation of T4 B. Physiologically active, but less than T3 C. Decreased in euthyroid sick syndrome D. Interferes with the measurement of serum T3

    A. Formed in the blood by degradation of T4

  • 6

    A patient has an elevated serum T3 and free T4 and undetectable TSH. What is the most likely cause of these results? A. Primary hyperthyroidism B. Secondary hyperthyroidism C. Euthyroid with increased thyroxine-binding proteins D. Euthyroid sick syndrome

    A. Primary hyperthyroidism

  • 7

    A serum thyroid panel reveals an increase in total T4, normal TSH, and normal free T4. What is the most likely cause of these results? A. Primary hyperthyroidism B. Secondary hyperthyroidism C. Euthyroid with increased thyroxine-binding protein D. Subclinical hypothyroidism

    C. Euthyroid with increased thyroxine-binding protein

  • 8

    Which statement about TSH and T4 in early pregnancy is correct? A. TSH and thyroid hormones fall B. TSH falls and thyroid hormones rise C. TSH and thyroid hormones both rise D. TSH rises and thyroid hormones fall

    B. TSH falls and thyroid hormones rise

  • 9

    In which case might a very low plasma TSH result not correlate with thyroid status? A. Euthyroid sick syndrome B. Congenital hypothyroidism C. When TBG is elevated D. After high-dose corticosteroid treatment

    D. After high-dose corticosteroid treatment

  • 10

    In which of the following cases is qualitative analysis of the drug usually adequate? A. To determine whether the dose of a drug with a low therapeutic index is likely to be toxic B. To determine whether a patient is complying with the physician’s instructions C. To adjust dose if individual differences or disease alter expected response D. To determine whether the patient has been taking amphetamines

    D. To determine whether the patient has been taking amphetamines

  • 11

    The term pharmacokinetics refers to the: A. Relationship between drug dose and the drug blood level B. Concentration of drug at its sites of action C. Relationship between blood concentration and therapeutic response D. The relationship between blood and tissue drug levels

    A. Relationship between drug dose and the drug blood level

  • 12

    The term pharmacodynamics is an expression of the relationship between: A. Dose and physiological effect B. Drug concentration at target sites and physiological effect C. Time and serum drug concentration D. Blood and tissue drug levels

    B. Drug concentration at target sites and physiological effect

  • 13

    The study of pharmacogenomics involves which type of testing? A. Family studies to determine the inheritance of drug resistance B. Testing drugs with cell cultures to determine the minimum toxic dosage C. Testing for single nucleotide polymorphisms known to affect drug metabolism D. Comparison of dose-response curves between family members

    C. Testing for single nucleotide polymorphisms known to affect drug metabolism

  • 14

    Select the five pharmacological parameters that determine serum drug concentration. A. Absorption, anabolism, perfusion, bioactivation, excretion B. Liberation, equilibration, biotransformation, reabsorption, elimination C. Liberation, absorption, distribution, metabolism, excretion D. Ingestion, conjugation, integration, metabolism, elimination

    C. Liberation, absorption, distribution, metabolism, excretion

  • 15

    Which route of administration is associated with 100% bioavailability? A. Sublingual B. Intramuscular C. Oral D. Intravenous

    D. Intravenous

  • 16

    The phrase “first-pass hepatic metabolism” means that: A. One hundred percent of a drug is excreted by the liver B. All drug is inactivated by hepatic enzymes after one pass through the liver C. Some drug is metabolized from the portal circulation, reducing bioavailability D. The drug must be metabolized in the liver to an active form

    C. Some drug is metabolized from the portal circulation, reducing bioavailability

  • 17

    Which formula can be used to estimate dosage needed to give a desired steady-state blood level? A. Dose per hour = clearance (milligrams per hour) × average concentration at steady state ÷ f B. Dose per day = fraction absorbed – fraction excreted C. Dose = fraction absorbed × (1/protein-bound fraction) D. Dose per day = half-life × log Vd (volume distribution)

    A. Dose per hour = clearance (milligrams per hour) × average concentration at steady state ÷ f

  • 18

    Which statement is true regarding the volume distribution (Vd) of a drug? A. Vd is equal to the peak blood concentration divided by the dose given B. Vd is the theoretical volume in liters into which the drug distributes C. The higher the Vd, the lower the dose needed to reach the desired blood level of drug D. The Vd is the principal determinant of the dosing interval

    B. Vd is the theoretical volume in liters into which the drug distributes

  • 19

    For drugs with first-order elimination, which statement about drug clearance is true? A. Clearance = elimination rate ÷ serum level B. It is most often performed by the liver C. It is directly related to half-life D. Clearance rate is independent of dose

    A. Clearance = elimination rate ÷ serum level

  • 20

    Which statement about steady-state drug levels is true? A. The absorbed drug must be greater than the amount excreted B. Steady state can be measured after two elimination half-lives C. Constant intravenous infusion will give the same minima and maxima as an oral dose D. Oral dosing intervals give peaks and troughs in the dose-response curve

    D. Oral dosing intervals give peaks and troughs in the dose-response curve

  • 21

    If too small a peak–trough difference is seen for a drug given orally, then: A. The dose should be decreased B. Time between doses should be decreased C. Dose interval should be increased D. Dose per day and time between doses should be decreased

    C. Dose interval should be increased

  • 22

    If the peak level is appropriate but the trough level too low at steady state, then the dose interval should: A. Be lengthened without changing the dose per day B. Be lengthened and dose rate decreased C. Not be changed, but dose per day increased D. Be shortened, but dose per day not changed

    D. Be shortened, but dose per day not changed

  • 23

    If the steady-state drug level is too high, the best course of action is to: A. Decrease the dose B. Decrease the dose interval C. Decrease the dose and decrease the dose interval D. Change the route of administration

    A. Decrease the dose

  • 24

    When should blood samples for trough drug levels be collected? A. 30 minutes after peak levels B. 45 minutes before the next dose C. 1–2 hours after the last dose D. Immediately before the next dose is given

    D. Immediately before the next dose is given

  • 25

    Blood sample collection time for peak drug levels: A. Varies with the drug, depending on its rate of absorption B. Is independent of drug formulation C. Is independent of the route of administration D. Is 30 minutes after a bolus intravenous injection is completed

    A. Varies with the drug, depending on its rate of absorption

  • 26

    Which could account for drug toxicity following a normally prescribed dose? A. Decreased renal clearance caused by kidney disease B. Discontinuance or administration of another drug C. Altered serum protein binding caused by disease D. All of these options

    D. All of these options

  • 27

    Select the elimination model that best describes most oral drugs. A. One compartment, linear first-order elimination B. Michaelis–Menton or concentration-dependent elimination C. Two compartment with a biphasic elimination curve D. Logarithmic elimination

    A. One compartment, linear first-order elimination

  • 28

    Drugs rapidly infused intravenously usually follow which elimination model? A. One compartment, first order B. One compartment, logarithmic C. Biphasic or two compartment with serum level rapidly falling in the first phase D. Michaelis–Menton or concentration-dependent elimination

    C. Biphasic or two compartment with serum level rapidly falling in the first phase

  • 29

    Which fact must be considered when evaluating a patient who displays signs of drug toxicity? A. Drug metabolites (e.g., N-acetylprocainamide) may need to be measured as well as parent drug B. If the concentration of total drug is within therapeutic limits, the concentration of free drug cannot be toxic C. If the drug has a wide therapeutic index, then it will not be toxic D. A drug level cannot be toxic if the trough is within the published therapeutic range

    A. Drug metabolites (e.g., N-acetylprocainamide) may need to be measured as well as parent drug

  • 30

    When a therapeutic drug is suspected of causing toxicity, which specimen is the most appropriate for an initial investigation? A. Trough blood sample B. Peak blood sample C. Urine at the time of symptoms D. Gastric fluid at the time of symptoms

    B. Peak blood sample

  • 31

    For a drug that follows first-order pharmacokinetics, adjustment of dosage to achieve the desired blood level can be made using which formula?

    A

  • 32

    For which drug group are both peak and trough measurements usually required? A. Antiarrhythmics B. Analgesics C. Tricyclic antidepressants D. Aminoglycoside antibiotics

    D. Aminoglycoside antibiotics

  • 33

    Which of the following statements about TLC for drug screening is true? A. Acidic drugs are extracted in an alkaline nonpolar solvent B. A drug is identified by comparing its Rf value and staining to standards C. Testing must be performed using a urine sample D. Opiates and other alkaloids are extracted at an acid pH

    B. A drug is identified by comparing its Rf value and staining to standards

  • 34

    The EMIT for drugs of abuse uses an: A. Antibody conjugated to a drug B. Enzyme conjugated to an antibody C. Enzyme conjugated to a drug D. Antibody bound to a solid phase

    C. Enzyme conjugated to a drug

  • 35

    Which statement about EMIT is true? A. Enzyme activity is inversely proportional to drug level B. Formation of NADH is monitored at 340 nm C. ALP is the commonly used conjugate D. Assay use is restricted to serum

    B. Formation of NADH is monitored at 340 nm

  • 36

    Which statement regarding cloned enzyme donor immunoassay (CEDIA) is true? A. The enzyme used is glucose-6-phosphate dehydrogenase B. The enzyme donor and acceptor molecules are fragments of β-galactosidase C. Drug concentration is inversely related to fluorescence D. The antibody is covalently linked to the enzyme donor

    B. The enzyme donor and acceptor molecules are fragments of ß-galactosidase

  • 37

    Which statement is true regarding particle-enhanced turbidimetric inhibition immunoassay methods for therapeutic drugs? A. Drug concentration is proportional to light scatter B. Magnetic separation is needed to remove unbound conjugate C. When particle-bound drug binds to antibody, light scattering is increased D. Two antibodies to the drug are needed

    C. When particle-bound drug binds to antibody, light scattering is increased

  • 38

    Quantitation of a drug by gas chromatography–mass spectroscopy (GC-MS) is usually performed in which mode? A. Total ion chromatography B. Selective ion monitoring C. Ion subtraction D. Selective reaction monitoring

    B. Selective ion monitoring

  • 39

    SITUATION: A urine sample is received in the laboratory with the appropriate custody control form, and a request for drug of abuse screening. Which test result would be cause for rejecting the sample? A. Temperature after collection 95°F B. pH 5.0 C. Specific gravity 1.005 D. Creatinine 5 mg/dL

    D. Creatinine 5 mg/dL

  • 40

    Which substance has the longest detection time? A. Amphetamines B. Cocaine C. Benzodiazepines D. Marijuana

    D. Marijuana

  • 41

    Which statement about the measurement of carboxyhemoglobin is true? A. Treatment with alkaline dithionite is used to convert carboxyhemoglobin to oxyhemoglobin B. Oxyhemoglobin has no absorbance at 540 nm, but carboxyhemoglobin does C. Bichromatic analysis is required in order to eliminate interference by oxyhemoglobin D. Carboxyhemoglobin can be measured by potentiometry

    C. Bichromatic analysis is required in order to eliminate interference by oxyhemoglobin

  • 42

    Which of the following statements about blood alcohol measurement is correct? A. Symptoms of intoxication usually begin when the level exceeds 0.05% w/v B. The skin puncture site should be disinfected with isopropanol C. The reference method is based upon enzymatic oxidation of ethanol by alcohol dehydrogenase D. Gas chromatography methods require extraction of ethanol from serum

    A. Symptoms of intoxication usually begin when the level exceeds 0.05% w/v

  • 43

    Which specimen is the sample of choice for lead screening? A. Whole blood B. Hair C. Serum D. Urine

    A. Whole blood

  • 44

    Which of the following enzymes can be used to measure plasma or serum salicylate? A. Peroxidase B. Salicylate esterase C. Salicylate hydroxylase D. p-Aminosalicylate oxidase

    C. Salicylate hydroxylase

  • 45

    Which of the following tests is least essential to the operation of an emergency department at a general hospital? A. Carboxyhemoglobin B. Osmolality C. Salicylate D. Lead

    D. Lead

  • 46

    Which of the following trace elements is considered an essential micronutrient? A. Thallium B. Aluminum C. Mercury D. Selenium

    D. Selenium

  • 47

    When measuring trace metals in blood other than lead, what type of tube should be used? A. Navy blue top B. Green top C. Purple top D. Red top

    A. Navy blue top

  • 48

    Which whole-blood level is suggestive of excessive exposure to lead in children but not adults? A. 4 μg/dL B. 14 μg/dL C. 28 μg/dL D. 32 μg/dL

    B. 14 μg/dL

  • 49

    What are the likely laboratory findings in a person suspected of having Wilson’s disease? A. Blood copper and ceruloplasmin low, urinary copper excretion high B. Blood and urine copper concentration high, ceruloplasmin low C. Blood and urine copper concentration high, ceruloplasmin high D. Blood and urine copper concentration low, ceruloplasmin low

    A. Blood copper and ceruloplasmin low, urinary copper excretion high

  • 50

    Which of the following tumor markers is classified as a tumor suppressor gene? A. BRCA-1 B. Carcinoembryonic antigen (CEA) C. Human chorionic gonadotropin (hCG) D. Nuclear matrix protein

    A. BRCA-1

  • 51

    In general, in which of the following situations is the analysis of a tumor marker most useful? A. Testing for recurrence B. Prognosis C. Screening D. Diagnosis

    A. Testing for recurrence

  • 52

    Which of the following enzymes is increased in persons with prostate and small-cell lung cancer? A. Creatine kinase-1 (CK-1) B. Gamma glutamyl transferase (GGT) C. Amylase D. Lactate dehydrogenase

    A. Creatine kinase-1 (CK-1)

  • 53

    Which of the following is the best analyte to monitor for recurrence of ovarian cancer? A. CA-15-3 B. CA-19-9 C. CA-125 D. CEA

    C. CA-125

  • 54

    Which tumor marker is associated with cancer of the urinary bladder? A. CA-19-9 B. CA-72-4 C. Nuclear matrix protein D. Cathepsin-D

    C. Nuclear matrix protein

  • 55

    A person presents with a cushingoid appearance and an elevated 24-hour urinary cortisol level. The plasma adrenocotropic hormone (ACTH) is very elevated, and the physician suspects the cause is ectopic ACTH production. Which test would be most useful in substantiating this diagnosis? A. Plasma cortisol B. CA-50 C. Alkaline phosphatase isoenzymes D. AFP

    C. Alkaline phosphatase isoenzymes

  • 56

    Which of the following tumor markers is used to monitor persons with breast cancer for recurrence of disease? A. Cathepsin-D B. CA-15-3 C. Retinoblastoma gene D. Estrogen receptor (ER)

    B. CA-15-3

  • 57

    Which of the following statements regarding the Philadelphia chromosome is true? A. It is seen exclusively in chronic myelogenous leukemia B. It results from a translocation C. It appears as a short-arm deletion of chromosome 21 D. It is associated with a poor prognosis

    B. It results from a translocation

  • 58

    What is the primary clinical utility of measuring CEA? A. Diagnosis of liver cancer B. Diagnosis of colorectal cancer C. Screening for cancers of endodermal origin D. Monitoring for recurrence of cancer

    D. Monitoring for recurrence of cancer

  • 59

    Which tumor marker is used to determine the usefulness of trastuzumab (Herceptin) therapy for breast cancer? A. PR B. CEA C. HER-2/neu D. Myc

    C. HER-2/ne

  • 60

    A person is suspected of having testicular cancer. Which type of hCG test would be most useful? A. Plasma immunoassay for intact hCG only B. Plasma immunoassay for intact hCG and the β-hCG subunit C. Plasma immunoassay for the free alpha and β-hCG subunits D. Urine assay for hCG β core

    B. Plasma immunoassay for intact hCG and the β-hCG subunit

  • 61

    A patient treated for a germ cell tumor has a total and free β-hCG assay performed prior to surgery. The result is 40,000 mIU/mL. One week following surgery, the hCG is 5,000 mIU/mL. Chemotherapy is started, and the hCG is measured 1 week later and found to be 10,000 mIU/mL. What does this indicate? A. Recurrence of the tumor B. Falsely increased hCG owing to drug interference with the assay C. Analytical error with the test reported as 5,000 mIU/mL D. Transient hCG increase caused by chemotherapy

    D. Transient hCG increase caused by chemotherapy

  • 62

    Which set of results for ER and PR is associated with the highest likelihood of a favorable response to treatment with estrogen-suppression therapy (tamoxifen)? A. ER positive, PR positive B. ER positive, PR negative C. ER negative, PR positive D. ER negative, PR negative

    A. ER positive, PR positive

  • 63

    Which type of cancer is associated with the highest level of AFP? A. Hepatoma B. Ovarian cancer C. Testicular cancer D. Breast cancer

    A. Hepatoma

  • 64

    Which of the following assays is recommended as a screening test for colorectal cancer in persons over 50 years old? A. CEA B. AFP C. Occult blood D. Fecal trypsin

    C. Occult blood

  • 65

    Which of the following assays is used to determine the risk of developing cancer? A. Epidermal growth factor receptor (EGF-R) B. Squamous cell carcinoma antigen (SCC) C. c-erb B-2 gene expression D. p53 gene mutation

    D. p53 gene mutation

  • 66

    A person has an elevated 24-hour urinary homovanillic acid (HVA) and vanillymandelic acid (VMA). Urinary metanephrines, chromogranin A, and neuron-specific enolase are also elevated but 5-hydroxyindoleacetic acid is within the reference range. What is the most likely diagnosis? A. Carcinoid tumors of the intestine B. Pheochromocytoma C. Neuroblastoma D. Pancreatic cancer

    C. Neuroblastoma

  • 67

    In which of the following conditions is PSA least likely to be increased? A. Precancerous lesions of the prostate B. Postprostate biopsy C. Benign prostatic hypertrophy D. Post–digital rectal examination

    D. Post–digital rectal examination

  • 68

    Which of the following statements regarding PSA is true? A. Complexed PSA in plasma is normally less than free PSA B. Free PSA below 25% is associated with malignant disease C. A total PSA below 4 ng/mL rules out malignant disease D. A total PSA above 10 ng/mL is diagnostic of malignant disease

    B. Free PSA below 25% is associated with malignant disease

  • 69

    A 55-year-old male with early stage prostate cancer diagnosed by biopsy had his prostate gland removed (simple prostatectomy). His PSA prior to surgery was 10.0 ng/mL. If the surgery was successful in completely removing the tumor cells, what would the PSA result be 1 month after surgery? A. Undetectable B. 1–3 ng/mL C. Less than 4 ng/mL D. Less than 10 ng/mL

    A. Undetectable